Histone deacetylase inhibitors (HDACi) induce Bim expression in various tumors, including multiple myeloma, melanoma, pancreatic adenocarcinoma, Burkitt's lymphoma and CML [240-245]. This evidence concerns the gene BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive.